Pharmaceutical distributors, manufacturers and logistics providers ask for debt recovery pharmaceutical supply support when a buyer, importer or freight forwarder stops paying against delivered stock, batch paperwork or a distribution agreement. SOLUTIO assesses the file before any recovery step and says plainly when the claim is not worth pursuing.
Pharmaceutical supply debt rarely starts as a simple non-payment. A manufacturer ships finished product to a distributor on agreed credit terms, and the distributor withholds payment after a price dispute, a rebate disagreement or a change of ownership. A distributor sells on to a pharmacy chain or hospital group that delays payment past the agreed period, citing budget cycles that have nothing to do with the goods received.
Cross-border freight adds another layer. A cold-chain carrier or forwarder raises a freight claim after a shipment is delayed, rejected at the border or held for import licensing, and the party who ordered the transport disputes the charge. Currency movement between order and delivery is another recurring trigger, particularly on long-lead active ingredient contracts where the buyer tries to renegotiate the price after the goods have already moved.
Pharmaceutical claims are decided on paper before they are decided on argument. The file that supports recovery contains the purchase order, the signed delivery note or warehouse receipt, the certificate of analysis and batch release documentation, and any temperature log where the goods travelled under cold-chain conditions. Import licence references and the customs entry connect the shipment to the buyer who received it.
A claim with a signed delivery note, a matching batch record and a clean set-off history moves quickly. A claim built only on an unsigned invoice and an email thread does not, whatever the contract value.
The most common defence is a quality complaint raised after payment falls due rather than at delivery: the batch was rejected, the product did not match specification, or a temperature excursion occurred in transit. The second is a set-off against rebates, marketing support or a prior credit note the buyer says was never issued. The third is a licensing argument – the import authorisation lapsed, or a distribution agreement was terminated before the disputed shipment moved.
A defence built on a quality complaint is defeated by the certificate of analysis, the batch release record and proof that the buyer accepted or resold the goods without formal rejection within the period the contract allows. A set-off defence is defeated by the credit note ledger. A licensing defence is defeated by showing the shipment moved under a valid authorisation at the time of delivery, regardless of what happened to the licence afterwards.
The file is assessed first: documents, the buyer's known trading position and the realistic value of pursuing the claim against the cost of doing so. Where the assessment supports action, a formal demand is issued under the contract, referencing the specific documents that establish delivery and acceptance. Where pre-legal contact does not resolve the balance, the file passes to admitted lawyers and licensed providers in the jurisdiction where the debtor is established, who take the claim into the appropriate court or arbitration forum if the contract provides for one.
Enforcement, where a judgment or award is obtained, follows the route available in the debtor's country. SOLUTIO coordinates the file through each stage and reports at each decision point rather than running the matter as a single unreviewed process.
We say so before instruction, not after fees have been incurred.
Yes, where the rejection is disputed. We assess whether the certificate of analysis, batch release record and delivery documentation support the seller's position before recommending any recovery step.
Yes. Cross-border pharmaceutical supply claims are handled through admitted lawyers and licensed providers in the jurisdiction where the debtor is established, coordinated through a single file on the creditor's side.
The credit note and rebate ledger are reviewed against the contract terms before any demand is issued, so the set-off claim is tested rather than accepted at face value.
An unpaid pharmaceutical invoice sits on a balance sheet that keeps moving: stock has already shipped, credit lines are already drawn, and the buyer's own position may be deteriorating while the file waits. The question worth answering first is not how much is owed, but whether the documentation and the debtor's position make recovery realistic before more is spent chasing it.